CanVIG-UK Resources

Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant

Approved: May 2022

Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant

Approved: May 2022

Example predictive testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant (reduced penetrance)

Approved: May 2022

Example predictive testing template for reporting a positive BRCA1 or PALB2 germline pathogenic/likely pathogenic variant

Approved: May 2022

Previous version: June 2021

Example predictive testing template for reporting a positive BRCA2 germline pathogenic/likely pathogenic variant

Approved: May 2022

Previous version: June 2021

Example predictive testing template for reporting a positive BRCA or PALB2 germline pathogenic/likely pathogenic variant

Approved: May 2022

Previous version (BRCA only): June 2021

Example predictive testing template for reporting a positive BRCA or PALB2 germline pathogenic/likely pathogenic variant (reduced penetrance)

Approved: May 2022

Example predictive testing template for reporting a negative variant for the R208 germline panel

Approved: May 2022

Previous version: June 2021

Example diagnostic testing template for reporting a CHEK2 or ATM germline pathogenic/likely pathogenic variant.

Approved: May 2022

Example diagnostic testing template for reporting ATM c.7271T>G p.(Val2424Gly) 

Approved: May 2022

Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.

Approved: May 2022

Previous version (BRCA only): June 2021

Example diagnostic testing template for reporting a reduced penetrance BRCA or PALB2 germline pathogenic/likely pathogenic variant.

Approved: May 2022

Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.

Approved: May 2022

Example diagnostic testing template for reporting where a variant of uncertain significance (VUS) is identified in the R208 panel (including CHEK2 and ATM)

Approved: May 2022

Previous version (BRCA only): June 2021

Example diagnostic testing template for reporting no germline pathogenic/likely pathogenic variants identified in the R208 panel (including CHEK2 and ATM)

Approved: May 2022

Previous version (BRCA only): June 2021

Example template for reporting a germline pathogenic/likely pathogenic variant in the Ovarian Cancer R207 diagnostic panel.

Approved: June 2022

Previous version: June 2021

Example template for reporting a germline variant of uncertain significance in the Ovarian Cancer R207 diagnostic panel.

Approved: June 2022

Example template for reporting no germline pathogenic/likely pathogenic variants in the Ovarian Cancer R207 diagnostic panel.

Approved: June 2022

Example Report Templates

External Resources

ACGS

The Association for Clinical Genomic Science brings together scientists working within genetics into one professional association.

JMG Paper

Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network.

 

Journal of Medical Genetics

Published: 13 March 2020.

UKCGG

The UK Cancer Genetics Group.

A multidisciplinary organisation for UK clinicians, counsellors & scientists interested in cancer susceptibility genetics.

ACMG

The American College of Medical Genetics variant interpretation framework can be found on their website.